Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1.

IM, Jacobson; RS Jr, Brown; J, McCone; M, Black; C, Albert; MS, Dragutsky; FA, Siddiqui; T, Hargrave; PY, Kwo; L, Lambiase; GW, Galler; V, Araya; B, Freilich; J, Harvey; LH, Griffel; CA, Brass

doi:10.1002/hep.21670

Public

Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1.

Shared by NobleBlocks on Oct 1, 2007 • 12:00 AM UTC

Authors:

Jacobson IM

Brown RS Jr

McCone J

Abstract

Unlabelled WIN-R (Weight-based dosing of pegINterferon alfa-2b and Ribavirin) was a multicenter, randomized, open-label, investigator-initiated trial involving 236 community and academic sites in the United States, comparing response to pegylated interferon (PEG-IFN) alfa-2b plus a flat or weight-ba...

Discussions